

Filter: Slovakia, minimal size of the groups n = 5

EQA round: VVV1/22 - Maternal Diagnostic Screening (Triple Test)

Deadline: 22.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(238) free beta-hCG														
Samples and groups		[U/L]			10							10	10	100%
Sample A1														
(60) Roche		45,4	2,3	5,0	10							10	10	100%
Other		45,8	1,6	3,6	9	0	CVPG	47	0,89	15%	39,9	54,1	9	
					1	0							1	
								1x 24						
Sample B1														
(60) Roche		55,0	3,4	6,2	10								10	100%
Other		55,3	1,4	2,5	9	0	CVPG	57,7	1,2	15%	49	66,4	9	
					1	0							1	
								1x 24						
(239) PAPP-A														
Samples and groups		[U/L]			13							10	10	100%
Sample A1														
(60) Roche		1,41	0,089	6,4	13								10	100%
Other		1,37	0,10	7,6	8	0	CVPG	1,4	0,033	15%	1,19	1,61	8	
					5	0							2	
								2x 24, 3x 29						
Sample B1														
(60) Roche		0,356	0,022	6,1	13								10	100%
Other		0,355	0,038	11	8	0	CVPG	0,365	0,0077	15%	0,31	0,42	8	
					5	0							2	
								2x 24, 3x 29						
Set 2														
(370) AFP														
Samples and groups		[µg/L]			14							11	10	91%
Sample A2														
(12) Beckman Coulter		32,4	2,8	8,8	14								11	91%
(60) Roche		30,6	2,2	7,2	5	0	CVPG	30,3	1,2	20%	24,2	36,4	5	
Other		34,9	3,2	9,1	5	0	CVPG	35,7	1,4	20%	28,5	42,9	5	
					4	0							1	
								1x 1, 3x 179						
Sample B2														
(12) Beckman Coulter		103	10	9,8	14								11	91%
(60) Roche		96,3	8,4	8,7	5	0	CVPG	97	3,5	20%	77,6	117	5	
Other		112	8,3	7,4	5	0	CVPG	114	4,2	20%	91,2	137	5	
					4	0							1	
								1x 1, 3x 179						
(373) hCG														
Samples and groups		[kU/L]			14							9	7	78%
Sample A2														
(60) Roche		28,0	7,1	25	14								9	78%
Other		25,1	1,2	4,8	5	0	CVPG	24,8	1,1	18%	20,3	29,3	5	
					9	0							4	
								1x 1, 4x 12, 1x 29, 1x 36, 2x 179						
Sample B2														
(60) Roche		27,7	6,1	22	14								9	89%
Other		24,3	2,2	8,9	5	0	CVPG	24	1,1	18%	19,6	28,4	5	
					9	0							4	
								1x 1, 4x 12, 1x 29, 1x 36, 2x 179						
(375) Estriol unconjug.														
Samples and groups		[nmol/L]			13							13	11	85%
Sample A2														
(12) Beckman Coulter		2,37	1,2	51	13								13	85%
(29) Siemens (Immulite)		3,48	0,75	21	6	0	CVPG	3,23	0,12	33%	2,16	4,3	6	
Other		1,63	0,16	9,8	7	0	CVPG	1,58	0,16	33%	1,05	2,11	7	
		5,97	1,9	31	13								13	92%
Sample B2														
(12) Beckman Coulter		7,50	0,74	9,8	6	0	CVPG	7,55	0,24	33%	5,05	10,1	6	
(29) Siemens (Immulite)		4,77	0,49	10	7	0	CVPG	4,54	0,55	33%	3,04	6,04	7	
1. trimester														
(240) free beta-hCG (MoM)														
Samples and groups		[MoM]			8							8	8	100%
Mother X1														
(60) Roche		0,940	0,089	9,5	8								8	100%
Other		0,950	0,074	7,8	7	0	CVPG	0,987	0,039	33%	0,661	1,32	7	
					1	0							1	
								1x 24						
Mother Y1														
(60) Roche		1,45	0,39	27	8								8	100%
Other		1,56	0,22	14	7	0	CVPG	1,65	0,089	33%	1,1	2,2	7	
					1	0							1	
								1x 24						

Filter: Slovakia, minimal size of the groups n = 5

EQA round: VVV1/22 - Maternal Diagnostic Screening (Triple Test)

Deadline: 22.04.2022

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability							
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(241) PAPP-A (MoM)	[MoM]				11							9	8	89%
Samples and groups														
Mother X1		0,826	0,16	20	11							9	8	89%
(60) Roche		0,810	0,10	13	7	0	CVPG	0,737	0,042	33%	0,493	0,981	7	
Other					4	0							2	
								2x 24, 2x 29						
Mother Y1		0,104	0,014	13	11							9	9	100%
(60) Roche		0,105	0,007	7,0	7	0	CVPG	0,102	,0049	33%	0,068	0,136	7	
Other					4	0							2	
								2x 24, 2x 29						
2. trimester														
(380) AFP (MoM)	[MoM]				14							14	12	86%
Samples and groups														
Mother X2		0,906	0,083	9,2	14		CVP	0,901	0,028	23%	0,693	1,11	14	12
All results		0,906	0,083	9,2	14	0							14	
Mother Y2		2,88	0,28	9,6	14		CVP	2,86	0,089	23%	2,2	3,52	14	12
All results		2,88	0,28	9,6	14	0							14	
(382) hCG (MoM)	[MoM]				14							9	8	89%
Samples and groups														
Mother X2		0,841	0,16	19	14							9	8	89%
(60) Roche		0,815	0,037	4,6	5	0	CVPG	0,861	0,087	33%	0,576	1,15	5	
Other					9	0							4	
								1x 1, 4x 12, 1x 29, 1x 36, 2x 179						
Mother Y2		0,824	0,12	15	14							9	9	100%
(60) Roche		0,780	0,03	3,8	5	0	CVPG	0,835	0,076	33%	0,559	1,12	5	
Other					9	0							4	
								1x 1, 4x 12, 1x 29, 1x 36, 2x 179						
(384) Estriol unconjug. (MoM)	[MoM]				13							13	12	92%
Samples and groups														
Mother X2		1,05	0,18	17	13							13	12	92%
(12) Beckman Coulter		1,04	0,27	27	6	0	CVPG	1,04	0,083	33%	0,696	1,39	6	
(29) Siemens (Immulin)		1,06	0,12	11	7	0	CVPG	0,978	0,12	33%	0,655	1,31	7	
Mother Y2		2,73	0,62	23	13							13	12	92%
(12) Beckman Coulter		2,43	0,58	24	6	0	CVPG	2,43	0,17	33%	1,62	3,24	6	
(29) Siemens (Immulin)		2,96	0,39	13	7	0	CVPG	2,75	0,31	33%	1,84	3,66	7	

st_kn_p

End of report

Printed: 05.05.2022